BACKGROUND: Pseudoprogression (psPD) represents false radiologic evidence of tumor progression and is observed in some glioblastoma (GBM) patients after postoperative chemoradiation (CRT) with temozolomide (TMZ). The ambiguity of the psPD diagnosis confounds identification of true progression and may lead to unnecessary interventions. The association between psPD and isocitrate dehydrogenase 1 (IDH1) mutational (mut) status is understudied, and its incidence may alter clinical decision making. METHODS: We retrospectively evaluated 120 patients with IDH1-mut (n = 60) and IDH1-wild-type (IDH-WT; [n = 60]) GBMs who received postoperative CRT with TMZ at 4 academic institutions. Response Assessment in Neuro-Oncology criteria were used to identify psPD rates in routine brain MRIs performed up to 90 days after CRT completion. RESULTS: Within 90 days of completing CRT, 9 GBM patients (1 [1.7%] IDH1-mut and 8 [13.3%] IDH1-WTs) demonstrated true progression, whereas 17 patients (3 [5%] IDH1-muts and 14 [23.3%] IDH1-WTs) demonstrated psPD (P = .004). IDH1-mut GBMs had a lower probability of psPD (hazard ratio: 0.173, 95% CI, 0.047-0.638, P = .008). Among the patients with radiologic signs suggestive of progression (n = 26), psPD was found to be the cause in 3 of 4 (75.0%) of the IDH1-mut GBMs and 14 of 22 (63.6%) of the IDH1-WT GBMs (P = .496). Median overall survival for IDH1-mut and IDH1-WT GBM patients was 40.3 and 23.0 months, respectively (P < .001). CONCLUSIONS: IDH1-mut GBM patients demonstrate lower absolute rates of psPD expression. Irrespective of GBM subtype, psPD expression was more likely than true progression within 90 days of completing CRT. Continuing adjuvant treatment for IDH1-mut GBMs is suggested if radiologic progression is suspected during this time interval.
BACKGROUND: Pseudoprogression (psPD) represents false radiologic evidence of tumor progression and is observed in some glioblastoma (GBM) patients after postoperative chemoradiation (CRT) with temozolomide (TMZ). The ambiguity of the psPD diagnosis confounds identification of true progression and may lead to unnecessary interventions. The association between psPD and isocitrate dehydrogenase 1 (IDH1) mutational (mut) status is understudied, and its incidence may alter clinical decision making. METHODS: We retrospectively evaluated 120 patients with IDH1-mut (n = 60) and IDH1-wild-type (IDH-WT; [n = 60]) GBMs who received postoperative CRT with TMZ at 4 academic institutions. Response Assessment in Neuro-Oncology criteria were used to identify psPD rates in routine brain MRIs performed up to 90 days after CRT completion. RESULTS: Within 90 days of completing CRT, 9 GBM patients (1 [1.7%] IDH1-mut and 8 [13.3%] IDH1-WTs) demonstrated true progression, whereas 17 patients (3 [5%] IDH1-muts and 14 [23.3%] IDH1-WTs) demonstrated psPD (P = .004). IDH1-mut GBMs had a lower probability of psPD (hazard ratio: 0.173, 95% CI, 0.047-0.638, P = .008). Among the patients with radiologic signs suggestive of progression (n = 26), psPD was found to be the cause in 3 of 4 (75.0%) of the IDH1-mut GBMs and 14 of 22 (63.6%) of the IDH1-WT GBMs (P = .496). Median overall survival for IDH1-mut and IDH1-WT GBM patients was 40.3 and 23.0 months, respectively (P < .001). CONCLUSIONS: IDH1-mut GBM patients demonstrate lower absolute rates of psPD expression. Irrespective of GBM subtype, psPD expression was more likely than true progression within 90 days of completing CRT. Continuing adjuvant treatment for IDH1-mut GBMs is suggested if radiologic progression is suspected during this time interval.
Authors: Arnab Chakravarti; Michael G Erkkinen; Ulf Nestler; Roger Stupp; Minesh Mehta; Ken Aldape; Mark R Gilbert; Peter McL Black; Jay S Loeffler Journal: Clin Cancer Res Date: 2006-08-01 Impact factor: 12.531
Authors: Quinn T Ostrom; Haley Gittleman; Peter Liao; Toni Vecchione-Koval; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2017-11-06 Impact factor: 12.300
Authors: E Van Mieghem; A Wozniak; Y Geussens; J Menten; S De Vleeschouwer; F Van Calenbergh; R Sciot; S Van Gool; O E Bechter; P Demaerel; G Wilms; P M Clement Journal: Eur J Neurol Date: 2013-05-17 Impact factor: 6.089
Authors: Jigisha P Thakkar; Therese A Dolecek; Craig Horbinski; Quinn T Ostrom; Donita D Lightner; Jill S Barnholtz-Sloan; John L Villano Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-07-22 Impact factor: 4.254
Authors: Stephanie E Combs; Stefan Rieken; Wolfgang Wick; Amir Abdollahi; Andreas von Deimling; Jürgen Debus; Christian Hartmann Journal: Radiat Oncol Date: 2011-09-13 Impact factor: 3.481
Authors: Kyu Sang Lee; Gheeyoung Choe; Kyung Han Nam; An Na Seo; Sumi Yun; Kyung Ju Kim; Hwa Jin Cho; Sung Hye Park Journal: Korean J Pathol Date: 2013-12-24
Authors: Michael Platten; Lukas Bunse; Antje Wick; Theresa Bunse; Lucian Le Cornet; Inga Harting; Felix Sahm; Khwab Sanghvi; Chin Leng Tan; Isabel Poschke; Edward Green; Sune Justesen; Geoffrey A Behrens; Michael O Breckwoldt; Angelika Freitag; Lisa-Marie Rother; Anita Schmitt; Oliver Schnell; Jörg Hense; Martin Misch; Dietmar Krex; Stefan Stevanovic; Ghazaleh Tabatabai; Joachim P Steinbach; Martin Bendszus; Andreas von Deimling; Michael Schmitt; Wolfgang Wick Journal: Nature Date: 2021-03-24 Impact factor: 49.962
Authors: Sebastian F Winter; Eugene J Vaios; Alona Muzikansky; Maria Martinez-Lage; Marc R Bussière; Helen A Shih; Jay Loeffler; Philipp Karschnia; Franziska Loebel; Peter Vajkoczy; Jorg Dietrich Journal: Oncologist Date: 2020-06-18